作者：
Maximilian A,Röhnert [1]
;
Michael,Kramer [2]
;
Jonas,Schadt [2]
;
Philipp,Ensel [2]
;
Christian,Thiede [2]
;
Stefan W,Krause [3]
;
Veit,Bücklein [4]
;
Jörg,Hoffmann [5]
;
Sonia,Jaramillo [6]
;
Richard F,Schlenk [7]
;
Christoph,Röllig [8]
;
Martin,Bornhäuser [8]
;
Nicholas,McCarthy [9]
;
Sylvie,Freeman [2]
;
Uta,Oelschlägel [2]
;
Malte,von Bonin [10]
作者单位：
Department of Medicine I, University Hospital Carl Gustav Carus TU Dresden, Dresden, Germany. Maximilian-Alexander.Roehnert@uniklinikum-dresden.de.
[1]
Department of Medicine I, University Hospital Carl Gustav Carus TU Dresden, Dresden, Germany.
[2]
AgenDix GmbH, Dresden, Germany.
[3]
Department of Medicine 5, Universitätsklinikum Erlangen, Erlangen, Germany.
[4]
Department of Medicine III, University Hospital LMU Munich, Munich, Germany.
[5]
Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany.
[6]
Department of Internal Medicine and Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Giessen and Marburg, Marburg, Germany.
[7]
Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
[8]
NCT Trial Center, National Center of Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.
[9]
National Center of Tumor Diseases, Dresden, Germany.
[10]
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
[11]
DOI
10.1038/s41375-022-01647-5
PMID
35851154
发布时间
2023-11-03
换一批
换一批
